Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD

Jonathan W. Goldman, Jonathan W. Riess, Byoung Chul Cho, Sarah B. Goldberg, Xiuning Le, Zofia Piotrowska, Isamu Okamoto, Helena A. Yu, Rosario García-Campelo, Javier de Castro Carpeño, Simon Ekman, Noemi Reguart, Marthe S. Paats, Sang-We Kim, Yu Jung Kim, Makoto Nishio, Kristen A. Marrone, Knut B. Smeland, Lizza E.L. Hendriks, Hiroaki Akamatsu, Junichi Shimizu, Paul E. Smith, Kwan Ho Tang, Jonathan M. Lehman, Adrianus J. de Langen

Open source

DOI: 10.1016/j.cllc.2026.09.001
Published: 2026-11
Container: Clinical Lung Cancer
Publisher: Elsevier BV
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1016/j.cllc.2026.09.001,
  title = {Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD},
  author = {Jonathan W. Goldman and Jonathan W. Riess and Byoung Chul Cho and Sarah B. Goldberg and Xiuning Le and Zofia Piotrowska and Isamu Okamoto and Helena A. Yu and Rosario García-Campelo and Javier de Castro Carpeño and Simon Ekman and Noemi Reguart and Marthe S. Paats and Sang-We Kim and Yu Jung Kim and Makoto Nishio and Kristen A. Marrone and Knut B. Smeland and Lizza E.L. Hendriks and Hiroaki Akamatsu and Junichi Shimizu and Paul E. Smith and Kwan Ho Tang and Jonathan M. Lehman and Adrianus J. de Langen},
  year = {2026},
  journal = {Clinical Lung Cancer},
  doi = {10.1016/j.cllc.2026.09.001},
  url = {https://doi.org/10.1016/j.cllc.2026.09.001}
}

RIS

TY  - JOUR
TI  - Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD
AU  - Jonathan W. Goldman
AU  - Jonathan W. Riess
AU  - Byoung Chul Cho
AU  - Sarah B. Goldberg
AU  - Xiuning Le
AU  - Zofia Piotrowska
AU  - Isamu Okamoto
AU  - Helena A. Yu
AU  - Rosario García-Campelo
AU  - Javier de Castro Carpeño
AU  - Simon Ekman
AU  - Noemi Reguart
AU  - Marthe S. Paats
AU  - Sang-We Kim
AU  - Yu Jung Kim
AU  - Makoto Nishio
AU  - Kristen A. Marrone
AU  - Knut B. Smeland
AU  - Lizza E.L. Hendriks
AU  - Hiroaki Akamatsu
AU  - Junichi Shimizu
AU  - Paul E. Smith
AU  - Kwan Ho Tang
AU  - Jonathan M. Lehman
AU  - Adrianus J. de Langen
PY  - 2026
JO  - Clinical Lung Cancer
DO  - 10.1016/j.cllc.2026.09.001
UR  - https://doi.org/10.1016/j.cllc.2026.09.001
ER  -

APA

Goldman, J. W., Riess, J. W., Cho, B. C., Goldberg, S. B., Le, X., Piotrowska, Z., Okamoto, I., Yu, H. A., García-Campelo, R., Carpeño, J. D. C., Ekman, S., Reguart, N., Paats, M. S., Kim, S., Kim, Y. J., Nishio, M., Marrone, K. A., Smeland, K. B., Hendriks, L. E., Akamatsu, H., Shimizu, J., Smith, P. E., Tang, K. H., Lehman, J. M., & Langen, A. J. D. (2026). Osimertinib Plus Platinum-based Chemotherapy in Patients With EGFR-Mutated Advanced NSCLC Post-progression on First-Line Osimertinib: ORCHARD. Clinical Lung Cancer. https://doi.org/10.1016/j.cllc.2026.09.001

Source records

crossref · retrieved 2026-11-11T01:49:24.213Z